Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Kang Sheng Bao to Develop Immune System Diagnostic Test for SuperNova

publication date: Mar 30, 2011
Shenzhen Kang Sheng Bao Bio-Technology (深圳康生保生物技术有限公司) has signed an agreement with SuperNova Diagnostics®, a Washington DC development stage company, giving KSB the responsibility to develop, manufacture and market diagnostic products that measure neopterin. Neopterin is a biomarker of immune system activity. KSB will use SuperNova’s AmpCrystal® platform. Two weeks ago, KSB and SuperNova announced KSB had licensed China rights for SuperNova’s platform. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital